Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Immunol. 2020 Nov 17;11:594735. doi: 10.3389/fimmu.2020.594735. eCollection 2020.
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4 helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.
白细胞介素-17 (IL-17) 是一种重要的促炎细胞因子，主要由 CD4 辅助性 T 细胞 (Th17 细胞) 和固有淋巴细胞亚群分泌。IL-17A 与炎症性疾病的发病机制有关，包括银屑病、特应性皮炎、化脓性汗腺炎、斑秃、毛发红糠疹、天疱疮和系统性硬化症。白细胞介素-23 (IL-23) 通过激活 Th17 细胞在刺激 IL-17 的产生中起关键作用。IL-23/IL-17 轴是炎症性疾病靶向治疗的重要途径。来自临床试验的新证据表明，针对 IL-23、IL-17 和肿瘤坏死因子的单克隆抗体在治疗银屑病、特应性皮炎、化脓性汗腺炎、毛发红糠疹、天疱疮和系统性硬化症患者方面具有疗效。在这里，我们总结了关于炎症性皮肤病中 IL-23/IL-17 轴的生物学、信号转导和病理生理学功能的最新知识。还讨论了目前针对该轴的生物制剂。
